论文部分内容阅读
目的探讨细菌溶解产物在预防慢性阻塞性肺疾病(COPD)急性发作中的成本-效益。方法使用成本-效益分析法,对象为接受细菌溶解产物治疗的COPD患者,成本为通过德尔菲法获得单次治疗COPD急性发作的医疗费用,效果指标为通过荟萃分析得到的随访期为12个月内患者COPD急性发作次数。使用单因素敏感性分析对参数变化对结果的影响进行识别。结果在对COPD的常规治疗中加入细菌溶解产物制剂能明显降低COPD患者12个月内的急性发作次数,降低患者的医疗负担,敏感性分析显示这一结果稳健。相比于单用常规治疗的患者,加用细菌溶解产物的患者平均少1.3次COPD急性发作,平均节省医疗费用10308元。结论对于COPD患者,在治疗中使用细菌溶解产物能减少急性发作次数,降低患者医疗费用。
Objective To investigate the cost-effectiveness of bacterial lysates in preventing acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Cost-benefit analysis was performed on patients with COPD treated with bacterial lysates at the cost of a single-pass medical treatment of acute exacerbation of COPD by the Delphi method. The outcome measure was a 12-month follow-up period by meta-analysis The number of patients with acute exacerbation of COPD. Single-factor sensitivity analysis was used to identify the effect of changes in parameters on the results. Results The addition of bacterial lysate preparations to routine treatment of COPD significantly reduced the number of acute attacks within 12 months of COPD patients and reduced the medical burden on patients. Sensitivity analysis showed that the results were robust. Patients treated with bacterial lysate took an average of 1.3 episodes of COPD exacerbations on average compared to those treated with conventional therapy alone, saving an average of $ 10,308 on medical costs. Conclusions For patients with COPD, the use of bacterial lysates in treatment can reduce the number of acute attacks and reduce the cost of medical care for patients.